Lipella OKd on Expanded Access Program for LP-310 in Oral Lichen Planus

  Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP).

LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory condition affecting the mucous membranes inside the mouth, often causing burning pain, white patches, swollen tissue and open sores. The condition impacts approximately 6 million Americans and currently has no FDA-approved therapies.

https://www.globenewswire.com/news-release/2025/02/06/3021821/0/en/Lipella-Pharmaceuticals-Granted-FDA-Approval-for-Expanded-Access-Program-for-LP-310-in-Oral-Lichen-Planus.html